Core Viewpoint - Arcellx, Inc. is experiencing significant market activity due to Gilead Sciences' planned acquisition, which is valued at $7.8 billion, marking a pivotal moment for the company and its stock performance [2][4]. Group 1: Stock Performance - Arcellx's stock surged approximately 80% in premarket trading following the acquisition announcement, with the current stock price at $113.81, reflecting a 77.52% increase and a $49.70 change [2]. - The stock has fluctuated between $113.80 and $114.26, marking its highest price over the past year, compared to a previous low of $47.86, indicating substantial growth [3]. Group 2: Acquisition Details - Gilead Sciences plans to acquire Arcellx in an all-cash deal valued at $7.8 billion, which is Gilead's largest acquisition since 2020, aimed at enhancing its cancer treatment portfolio [2]. - The acquisition involves acquiring the remaining shares of Arcellx, further solidifying Gilead's position in the biotech sector [4]. Group 3: Market Capitalization and Trading Volume - Arcellx's market capitalization is approximately $6.58 billion, with a trading volume of around 18.59 million shares, reflecting strong investor interest following the acquisition news [4].